Pearl Diagnostics
Reviewed active Updated Sep 2, 2026This profile is AI-generated. If you spot an error, please help us fix it by sharing a URL to the correct information.
Founders
About
Pearl Diagnostics is a Baltimore-based biotech and Johns Hopkins University spinout founded in 2014 (previously operating as MycoMed Technologies, LLC and MycoMedDx Inc.), developing noninvasive fungal infection tests including a urine-based diagnostic for aspergillosis 12. CEO Eric Gornstein — who joined in fall 2025 — noted “It’s extraordinarily rare for a company at the Series A level to have a commercial product,” highlighting the company’s advanced commercial stage 1. The Series A proceeds will fund the US commercial launch following recent FDA clearance and support expansion into Europe, where Pearl has secured CE approval 1. The company is headquartered at 1812 Ashland Avenue, Suite G32, Baltimore, MD 21205 2. Its board of directors includes Kieren Marr, Brad Spellberg, John Cammack, and Eric Gornstein 2.
Funding History
| Date | Round | Amount | Lead | Co-investors |
|---|---|---|---|---|
| 2026-04-24 | Series A | $11.15M | Undisclosed | 21 undisclosed accredited investors 123 |
Pearl Diagnostics raised $11,150,000 (reported by Technical.ly as $11.2M) in a Regulation D Rule 506(b) exempt equity offering 12. Per the Form D, the first sale date was March 19, 2026; the filing was signed by CEO Eric Gornstein on April 2, 2026 and submitted to the SEC on April 21, 2026, with public coverage by Technical.ly on April 24, 2026 12. The round was fully subscribed at the $11.15M target with 21 accredited investors and a $56,544 minimum investment per investor 2. No lead investor or participating firms were publicly disclosed in the filing or in press coverage 12.
What Investors Say
No independently sourced investor quotes found. The round was disclosed via SEC Form D filing without a press release, and no participating investors have publicly announced their involvement.
What Founders Say
CEO Eric Gornstein on the company’s commercial readiness at Series A: “It’s extraordinarily rare for a company at the Series A level to have a commercial product.” 1
Sources
-
Technical.ly, “Pearl Diagnostics raises $11.2M Series A to launch US sales,” April 24, 2026. Accessed April 2026. https://technical.ly/entrepreneurship/pearl-diagnostics-raises-series-a-maryland-money-moves/↩↩↩↩↩↩↩↩
-
SEC Form D, Pearl Diagnostics, Inc. (CIK 0001922830), Accession No. 0001922830-26-000003, filed April 21, 2026; first sale date March 19, 2026; total offering and amount sold $11,150,000; 21 accredited investors; minimum investment $56,544; signed by Eric Gornstein April 2, 2026. Board of directors: Kieren Marr, Brad Spellberg, John Cammack, Eric Gornstein. Accessed September 2026. https://www.sec.gov/Archives/edgar/data/1922830/000192283026000003/primary_doc.xml↩↩↩↩↩↩↩↩
-
SEC EDGAR filing index, Pearl Diagnostics, Inc. Form D, April 21, 2026. Accessed September 2026. https://www.sec.gov/cgi-bin/browse-edgar?action=getcompany&CIK=0001922830&type=D&dateb=&owner=exclude&count=↩